Individual choice of menopausal hormone therapy
The goal of anti-aging menopausal hormone therapy (MHT) lies in maintenance and restoration of the major organs and body systems, thus achieving two main effects: increasing life expectancy and improving its quality, which is fully consistent with the desires of women in perimenopausal and postmenop...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Berlin A.V.
2016-08-01
|
| Series: | Гинекология |
| Subjects: | |
| Online Access: | https://gynecology.orscience.ru/2079-5831/article/viewFile/28562/pdf |
| _version_ | 1818143905128906752 |
|---|---|
| author | T V Ovsyannikova I A Kulikov |
| author_facet | T V Ovsyannikova I A Kulikov |
| author_sort | T V Ovsyannikova |
| collection | DOAJ |
| description | The goal of anti-aging menopausal hormone therapy (MHT) lies in maintenance and restoration of the major organs and body systems, thus achieving two main effects: increasing life expectancy and improving its quality, which is fully consistent with the desires of women in perimenopausal and postmenopausal women. MHT started in the menopausal transition period is not only the treatment of early symptoms of menopause, but menopause itself and prevention of late complications. The article discusses the possibility and efficacy of Angeliq® Micro containing reduced doses of estrogen and progestogen (17β-estradiol 0.5 mg + drospirenone 0.25 mg). Indications for its purpose is to maintain moderate to severe hot flashes in postmenopausal women with an intact uterus. |
| first_indexed | 2024-12-11T11:39:05Z |
| format | Article |
| id | doaj.art-a285504b79f34cb192b79faeb5a40eb3 |
| institution | Directory Open Access Journal |
| issn | 2079-5696 2079-5831 |
| language | Russian |
| last_indexed | 2024-12-11T11:39:05Z |
| publishDate | 2016-08-01 |
| publisher | IP Berlin A.V. |
| record_format | Article |
| series | Гинекология |
| spelling | doaj.art-a285504b79f34cb192b79faeb5a40eb32022-12-22T01:08:39ZrusIP Berlin A.V.Гинекология2079-56962079-58312016-08-01184596225692Individual choice of menopausal hormone therapyT V Ovsyannikova0I A Kulikov1People’s Friendship University of RussiaI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationThe goal of anti-aging menopausal hormone therapy (MHT) lies in maintenance and restoration of the major organs and body systems, thus achieving two main effects: increasing life expectancy and improving its quality, which is fully consistent with the desires of women in perimenopausal and postmenopausal women. MHT started in the menopausal transition period is not only the treatment of early symptoms of menopause, but menopause itself and prevention of late complications. The article discusses the possibility and efficacy of Angeliq® Micro containing reduced doses of estrogen and progestogen (17β-estradiol 0.5 mg + drospirenone 0.25 mg). Indications for its purpose is to maintain moderate to severe hot flashes in postmenopausal women with an intact uterus.https://gynecology.orscience.ru/2079-5831/article/viewFile/28562/pdfmenopausal hormone therapypostmenopauseangeliq micro |
| spellingShingle | T V Ovsyannikova I A Kulikov Individual choice of menopausal hormone therapy Гинекология menopausal hormone therapy postmenopause angeliq micro |
| title | Individual choice of menopausal hormone therapy |
| title_full | Individual choice of menopausal hormone therapy |
| title_fullStr | Individual choice of menopausal hormone therapy |
| title_full_unstemmed | Individual choice of menopausal hormone therapy |
| title_short | Individual choice of menopausal hormone therapy |
| title_sort | individual choice of menopausal hormone therapy |
| topic | menopausal hormone therapy postmenopause angeliq micro |
| url | https://gynecology.orscience.ru/2079-5831/article/viewFile/28562/pdf |
| work_keys_str_mv | AT tvovsyannikova individualchoiceofmenopausalhormonetherapy AT iakulikov individualchoiceofmenopausalhormonetherapy |